Stocksigma LogoStocksigma Logo

Balaxi Pharmaceuticals Q2 FY27 Results and WHO-GMP Certification Milestone

Balaxi Pharmaceuticals reported consolidated revenue from operations of ₹8,137.23 lakhs for the quarter ended 30th Sep'26, up 44.85% YoY from ₹5,617.53

Balaxi Pharmaceuticals Q2 FY27 Results and WHO-GMP Certification Milestone

Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:31 pm

Balaxi Pharmaceuticals Q2 FY27 Results and WHO-GMP Certification Milestone Balaxi Pharmaceuticals reported consolidated revenue from operations of ₹8,137.23 lakhs for the quarter ended 30th Sep'26, up 44.85% YoY from ₹5,617.53 lakhs, with net profit surging to ₹115.02 lakhs from ₹20.90 lakhs in the prior-year period. Operationally, the company secured WHO-GMP certification from CDSCO for its Jadcherla formulation facility, scaling commercial production for Angola and Dominican Republic markets with 22 manufactured products and total approvals reaching 34. Additionally, Pranav Maheshwari was re-designated as President – Business and Corporate Strategy, effective 12th Nov'26.

Original exchange filing (PDF)

More announcements from Balaxi Pharmaceuticals Ltd

All Balaxi Pharmaceuticals Ltd announcements